公司比較

簡介

Sarepta Therapeutics is the leader in treatments for Duchenne muscular dystrophy (DMD) — a fatal muscle-wasting disease affecting young boys. Its gene therapy Elevidys is the first approved treatment to address the genetic root cause.

營收

$1.9B

新聞缺口信號

此股票代碼沒有新聞缺口數據。

機構信號

此代號沒有13F信號記錄。

級聯模式

未出現在任何追蹤的級聯模式中。

關鍵關係

簡介

NVIDIA is the dominant designer of graphics processing units and AI accelerator chips. Its data-center GPU monopoly powers the generative-AI revolution, with the H100 and successor Blackwell GPUs serving as the de-facto standard for training and running large language models.

營收

$130.5B

新聞缺口信號

機構信號

級聯模式

關鍵關係